Takeda Pharmaceutical Company Limited (FRA:TKD)

Germany flag Germany · Delayed Price · Currency is EUR
25.87
+0.15 (0.58%)
At close: Jun 27, 2025, 10:00 PM CET
8.29%
Market Cap 40.63B
Revenue (ttm) 28.31B
Net Income (ttm) 666.82M
Shares Out n/a
EPS (ttm) 0.42
PE Ratio 60.94
Forward PE n/a
Dividend 1.21 (4.67%)
Ex-Dividend Date Mar 28, 2025
Volume n/a
Average Volume 138
Open 25.73
Previous Close 25.72
Day's Range 25.73 - 25.87
52-Week Range 23.89 - 28.29
Beta n/a
RSI 51.51
Earnings Date Jul 30, 2025

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 49,281
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TKD
Full Company Profile

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.